Article and Video CATEGORIES
Denise has over 30 years of varying experience in the healthcare arena. In August 2009 she joined The Global Resource for Advancing Cancer Education as one of its first employees. She has grown with the organization and now oversees the operational movement of programs, efficiency, and effectiveness within the organization, as well as the daily processes and functions.
Who, What, Why, When and How?
The Global Resource for Advancing Cancer Education (GRACE)
in partnership with
Swedish Cancer Institute
presents:
Local Therapies for Metastatic Lung Cancer
Who, What, Why, When and How?
Swedish Cancer Center, Tesh Conference Room
Saturday, November 10, 2018 | 10:00 am– 1:00 pm
Join GRACE and Swedish Cancer Institute for our live event featuring Drs H. Jack West, Eric Vallieres, Vivek Mehta, Puneeth Iyengar.
In this 2018 OncTalk series, the docs will discuss local therapies for metastatic lung cancer. To view the full AGENDA, please visit this link.
Please register to join us in person at Swedish Medical Center, or join the live webcast.
Don't miss out. This event is free but space is limited! Reserve your spot!
To register please click here.
Our faculty will discuss the following topics:
- Newer Technologies in Radiation
- Novel Indications for Local Therapy in Advanced NSCLC
- The Growing Potential Utility of Surgery in Advanced NSCLC
- Systemic Therapies for Advanced NSCLC
- Panel Discussion and Question and Answer time.
Join us after for coffee and tea, and light snacks. 
To view the full agenda, please visit this link.
Please feel free to offer comments and raise questions in our
discussion forums.
Related Content
Forum Discussions
Hi elysianfields and welcome to Grace. I'm sorry to hear about your father's progression.
Unfortunately, lepto remains a difficult area to treat. Recently FDA approved the combo Lazertinib and Amivantamab...
Hello Janine, thank you for your reply.
Do you happen to know whether it's common practice or if it's worth taking lazertinib without amivantamab? From all the articles I've come across...
Hi elysianfields,
That's not a question we can answer. It depends on the individual's health. I've linked the study comparing intravenous vs. IV infusions of the doublet lazertinib and amivantamab...
Recent Comments
That's…